Show simple item record

dc.contributor.author Yeganeh, Behzad
dc.contributor.author Wiechec, Emmilia
dc.contributor.author Ande, Sudharsana
dc.contributor.author Sharma, Pawan
dc.contributor.author Moghadam, Adel Rezaei
dc.contributor.author Post, Martin
dc.contributor.author Freed, Darren H.
dc.contributor.author Hashemi, Mohammad
dc.contributor.author Shojaei, Shahla
dc.contributor.author Zeki, Amir A.
dc.contributor.author Ghavami, Saeid
dc.date.accessioned 2014-03-07T17:54:49Z
dc.date.available 2014-03-07T17:54:49Z
dc.date.issued 2014-02-26
dc.identifier.citation Pharmacology and Therapeutics, 2014 en_US
dc.identifier.issn 0163-7258
dc.identifier.uri http://hdl.handle.net/1993/23336
dc.description.abstract The cholesterol biosynthesis pathway, also known as the mevalonate (MVA) pathway, is an essential cellular pathway that is involved in diverse cell functions. The enzyme 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase (HMGCR) is the rate-limiting step in cholesterol biosynthesis and catalyzes the conversion of HMG-CoA to MVA. Given its role in cholesterol and isoprenoid biosynthesis, the regulation of HMGCR has been intensely investigated. Because all cells require a steady supply of MVA, both the sterol (i.e. cholesterol) and non-sterol (i.e. isoprenoid) products of MVA metabolism exert coordinated feedback regulation on HMGCR through different mechanisms. The proper functioning of HMGCR as the proximal enzyme in the MVA pathway is essential under both normal physiologic conditions and in many diseases given its role in cell cycle pathways and cell proliferation, cholesterol biosynthesis and metabolism, cell cytoskeletal dynamics and stability, cell membrance structure and fluidity, mitochondrial function, proliferation, and cell fate. The blockbuster statin drugs ('statins') directly bind to and inhibit HMGCR, and their use for the past thirty years has revolutionized the treatment of hypercholesterolemia and cardiovascular diseases, in particular coronary heart disease. Initially thought to exert their effects through cholesterol reduction, recent evidence indicates that statins also have pleiotropic immunomodulatory properties independent of cholesterol lowering. In this review we will focus on the therapeutic applications and mechanisms involved in the MVA cascade including Rho GTPase and Rho kinase (ROCK) signaling, statin inhibition of HMGCR, geranylgeranyltransferase (GGTase) inhibition, and farnesyltransferase (FTase) inhibition in cardiovascular disease, pulmonary diseases (e.g. asthma and chronic obstructive pulmonary disease (COPD), and cancer). en_US
dc.description.sponsorship A career-developing award provided by the Parker B Francis Foundation supported Saeid Ghavami. Pawan Sharma was supported by a CIHR postdoctoral fellowship award. Amir A.Zeki was supported by the National Center for Advancing Translational Sciences, National Institutes of Health (NIH), through grant #UL1 TR000002; and CTSC NIH KL2 (K12) Award TR000134. en_US
dc.language.iso en en_US
dc.publisher Elsevier en_US
dc.rights info:eu-repo/semantics/openAccess
dc.subject statins en_US
dc.subject asthma en_US
dc.subject cancer en_US
dc.subject chronic obstructive pulmonary disease en_US
dc.subject fibrosis en_US
dc.title Targeting the Mevalonate Cascade as a New Therapeutic Approach in Heart Disease, Cancer and Pulmonary Disease en_US
dc.type Article en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.1016/j.pharmthera.2014.02.007


Files in this item

This item appears in the following Collection(s)

Show simple item record

View Statistics